Prognostic Value of High-Dose Dipyridamole Stress Myocardial Contrast Perfusion Echocardiography

• DOI: 10.1161/circulationaha.112.110031
• Publication Date: 2012-08-08T05:21:11Z
• Authors: Nicola Gaibazzi; Claudio Reverberi; Valentina Lorenzoni; Sabrina Molinaro; Thomas R. Porter
• Keywords: Dipyridamole

Background— The addition of myocardial perfusion (MP) imaging during dipyridamole real-time contrast echocardiography improves the sensitivity to detect coronary artery disease, but its prognostic value predict hard cardiac events in large numbers patients with known or suspected disease remains unknown. Methods and Results— We studied 1252 use followed them for a median 25 months. MP regarding death nonfatal infarction was determined related wall motion (WM), clinical risk factors, rest ejection fraction by Cox proportional-hazards models, C index, reclassification analysis. A total 59 (4.7%) occurred follow-up (24 deaths, 35 infarctions). 2-year event-free survival 97.9% normal WM, 91.9% isolated reversible defects 67.4% both WM abnormalities ( P <0.001). By multivariate analysis independent predictors were age (hazard ratio 1.05, 95% confidence interval [CI], 1.02–1.08), sex ratio, 2.36; CI, 1.32–4.23), 3.88; 1.83–8.21), 4.51; 2.25–9.07). Reversible added incremental predictive benefit over response factors =0.001). Conclusions— using provides independent, information disease. Patients responses have better outcome than WM; worst outcome.